{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:54:34Z","timestamp":1788317674250,"version":"build-2803163510"},"reference-count":92,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of KwaZulu-Natal Research Office"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Camptothecin (CPT) and its derivatives, irinotecan and topotecan, are integral components of cancer chemotherapy, often used in combination therapies. This meta-analysis evaluates the efficacy of CPT-based combination treatments in cancer patients. Methods: We systematically searched the literature database using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist for articles published between 2000 and 2022. Published studies were retrieved through an electronic search on the Web of Science, PubMed, and Google Scholar databases. A total of 138 studies were downloaded and examined, and 71 eligible studies were selected for meta-analysis after excluding studies that did not meet the inclusion criteria. Results: Ultimately, a total of 71 studies were included in the analysis, comprising non-small cell lung cancer (NSCLC), colorectal cancer (COLRC), oesophageal\/gastric cancer (O\/GC), and small cell lung cancer (SCLC). For NSCLC, the objective response rate (RR) was 31.8% (95% CI: 27.3\u201337.1%, p = 0.025), with irinotecan plus cisplatin showing significantly higher efficacy compared to other irinotecan-based combinations. In COLRC, irinotecan and 5-fluorouracil\/leucovorin plus bevacizumab demonstrated superior efficacy with a RR of 44% (95% CI: 34\u201358, p &lt; 0.001) and minimal haematological toxicity. In O\/GC, irinotecan-based combinations showed an average RR of 43% (95% CI: 27\u201370, p &lt; 0.001) and average overall survival (OS) and progression-free survival (PFS) rates of 10.2 and 5.5 months, respectively. For SCLC, irinotecan-based combinations had a higher control response than topotecan-based ones, while the latter exhibited higher rates of stable and progressive disease. The overall RR for SCLC was 45% (95% CI: 34.3\u201360.2, p &lt; 0.001). Conclusions: The existing evidence underscored the potential of CPT-based combination therapy in various cancers. Among the various combinations discussed in this analysis, irinotecan plus cisplatin demonstrated the highest objective RR in 12 trials focused on NSCLC. This study provides valuable insights into potential treatment strategies for various types of cancer, emphasising the importance of personalised and tailored approaches to maximise efficacy and minimise adverse effects.<\/jats:p>","DOI":"10.3390\/cancers16223802","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T05:21:59Z","timestamp":1731388919000},"page":"3802","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Camptothecin and Its Derivatives from Traditional Chinese Medicine in Combination with Anticancer Therapy Regimens: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1316-5376","authenticated-orcid":false,"given":"Paul O.","family":"Odeniran","sequence":"first","affiliation":[{"name":"Department of Veterinary Parasitology and Entomology, University of Ibadan, Ibadan 200001, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0641-1452","authenticated-orcid":false,"given":"Paradise","family":"Madlala","sequence":"additional","affiliation":[{"name":"HIV Pathogenesis Programme, School of Laboratory Medicine and Medical Science, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban 4000, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0808-9201","authenticated-orcid":false,"given":"Nompumelelo P.","family":"Mkhwanazi","sequence":"additional","affiliation":[{"name":"HIV Pathogenesis Programme, School of Laboratory Medicine and Medical Science, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban 4000, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud E. S.","family":"Soliman","sequence":"additional","affiliation":[{"name":"Molecular Bio-Computation and Drug Design Lab, School of Health Sciences, University of Kwazulu-Natal, Durban 4000, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10147-021-02108-2","article-title":"Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050","volume":"27","author":"Sharma","year":"2022","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2019.0349","article-title":"Prevalence and Nondisclosure of Complementary and Alternative Medicine Use in Patients with Cancer and Cancer Survivors in the United States","volume":"5","author":"Sanford","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/1759-7714.12270","article-title":"Traditional Chinese medicine and cancer: History, present situation, and development","volume":"6","author":"Liu","year":"2015","journal-title":"Thorac. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1021\/cr60284a004","article-title":"Camptothecin","volume":"73","author":"Schultz","year":"1973","journal-title":"Chem. Rev."},{"key":"ref_6","first-page":"283","article-title":"Novel Camptothecin Derivatives","volume":"19","author":"Legarza","year":"2005","journal-title":"In Vivo"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/sj.bjc.6602748","article-title":"Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: A multicenter randomised phase II study","volume":"93","author":"Georgoulias","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12032-024-02527-x","article-title":"Camptothecin and its derivatives: Advancements, mechanisms and clinical potential in cancer therapy","volume":"41","author":"Kamle","year":"2024","journal-title":"Med. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1021\/acs.jmedchem.3c02115","article-title":"Unleashing the Potential of Camptothecin: Exploring Innovative Strategies for Structural Modification and Therapeutic Advancements","volume":"67","author":"Chen","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ghanbari-Movahed, M., Kaceli, T., Mondal, A., Farzaei, M.H., and Bishayee, A. (2021). Recent Advances in Improved Anticancer Efficacies of Camptothecin Nano-Formulations: A Systematic Review. Biomedicines, 9.","DOI":"10.3390\/biomedicines9050480"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jclinepi.2011.11.014","article-title":"Assessing risk of bias in prevalence studies: Modification of an existing tool and evidence of interrater agreement","volume":"65","author":"Hoy","year":"2012","journal-title":"J. Clin. Epidemiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence","volume":"67","author":"Barendregt","year":"2013","journal-title":"J. Epidemiol. Community Health"},{"key":"ref_14","unstructured":"Barendregt, J.J., and Doi, S.A. (2023, August 07). MetaXL User Guide. Available online: www.epigear.com."},{"key":"ref_15","first-page":"413","article-title":"A phase II study of irinotecan combined with cisplatin in non-small cell lung cancer. CPT-11 Lung Cancer Study Group","volume":"27","author":"Nagao","year":"2000","journal-title":"Gan Kagaku Ryoho"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0169-5002(00)80089-6","article-title":"The final results of a randomized phase III trial comparing irinotecan (CPT-11) and cisplatin (CDDP) with vindesine (VDS) and CDDP in advanced non-small cell lung cancer (NSCLC)","volume":"1","author":"Takiguchi","year":"2000","journal-title":"Lung Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1054\/bjoc.2001.1861","article-title":"Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: A phase II study of Okayama Lung Cancer Study Group","volume":"85","author":"Ueoka","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_18","first-page":"68","article-title":"Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: A multicenter phase II study","volume":"7","author":"Jagasia","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0169-5002(01)00384-1","article-title":"Cisplatin and Irinotecan (CPT-11) as Second-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer","volume":"34","author":"Kakolyris","year":"2001","journal-title":"Lung Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0169-5002(02)00304-5","article-title":"Phase II Study of Irinotecan and Carboplatin for Advanced Non-Small Cell Lung Cancer","volume":"38","author":"Takeda","year":"2002","journal-title":"Lung Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000070286","article-title":"Phase II study of irinotecan and ifosfamide in patients with advanced non-small cell lung cancer","volume":"64","author":"Ichiki","year":"2003","journal-title":"Oncology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.bjc.6600725","article-title":"Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer","volume":"88","author":"Negoro","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0169-5002(02)00512-3","article-title":"Three-Week Schedule of Irinotecan and Cisplatin in Advanced Non-Small Cell Lung Cancer: A Multicentre Phase II Study","volume":"39","author":"Cardenal","year":"2003","journal-title":"Lung Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00280-004-0805-2","article-title":"Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer","volume":"54","author":"Fukuda","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.bjc.6601462","article-title":"Randomised phase II study of docetaxel\/cisplatin vs docetaxel\/irinotecan in advanced non-small-cell lung cancer: A West Japan Thoracic Oncology Group Study (WJTOG9803)","volume":"90","author":"Yamamoto","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.lungcan.2004.01.008","article-title":"Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB\/IV non-small cell lung cancer\u2014Experience from a prematurely closed phase II study","volume":"45","author":"Raez","year":"2004","journal-title":"Lung Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/annonc\/mdh104","article-title":"Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC","volume":"15","author":"Lima","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.lungcan.2005.05.004","article-title":"Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: A multicentre phase II study","volume":"50","author":"Ziotopoulos","year":"2005","journal-title":"Lung Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/sj.bjc.6602827","article-title":"Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: A phase I-II trial","volume":"93","author":"Stathopoulos","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.4161\/cbt.4.12.2168","article-title":"Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer","volume":"4","author":"Murren","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/01.coc.0000231432.22998.6a","article-title":"Phase II study of 3-week scheduling of irinotecan in combination with cisplatin in patients with advanced nonsmall-cell lung cancer","volume":"29","author":"Saito","year":"2006","journal-title":"Am. J. Clin. Oncol. Cancer Clin. Trials"},{"key":"ref_32","first-page":"4697","article-title":"Weekly administration of irinotecan (CPT -11) plus cisplatin for non-small cell lung cancer","volume":"26","author":"Hino","year":"2006","journal-title":"Anticancer Res."},{"key":"ref_33","first-page":"777","article-title":"Irinotecan plus cisplatin for the treatment of advanced non-small cell lung cancer","volume":"28","author":"Zhang","year":"2006","journal-title":"Chin. J. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S1556-0864(15)31629-4","article-title":"A Phase II Study of Irinotecan and Carboplatin in Advanced Non-small Cell Lung Cancer with Pharmacogenomic Analysis: Final Report","volume":"1","author":"Pillot","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"ref_35","first-page":"2506","article-title":"Phase II Study of Cisplatin Combined to Irinotecan Administered Alternatingly with Docetaxel in Advanced Non-Small Cell Lung Cancer","volume":"90","author":"Charoentum","year":"2007","journal-title":"J. Med. Assoc. Thail."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.bjc.6603493","article-title":"Uracil\/ftorafur\/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: Results of randomised phase II study","volume":"96","author":"Bajetta","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/S1359-6349(03)90328-4","article-title":"Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): Updated results of a randomized phase II trial","volume":"1","author":"Grothey","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/annonc\/mdi185","article-title":"Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: A Southern Italy Cooperative Oncology Group phase III trial","volume":"16","author":"Comella","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/sj.bjc.6602860","article-title":"Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer","volume":"93","author":"Feliu","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(07)61087-3","article-title":"Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial","volume":"370","author":"Seymour","year":"2007","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/annonc\/mdi047","article-title":"A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: Efficacy, quality-of-life and toxicity","volume":"16","author":"Borner","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/annonc\/mdp359","article-title":"Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: Results of a randomized phase II study","volume":"21","author":"Rosati","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.2010.31.1936","article-title":"Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104\u2014A randomized trial of the German AIO CRC study group","volume":"29","author":"Moosmann","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1200\/JCO.2005.07.113","article-title":"Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A Multicenter Study of the Gruppo Oncologico Dell\u2019Italia Meridionale","volume":"23","author":"Colucci","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1200\/JCO.2005.05.546","article-title":"Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986","volume":"23","author":"Greil","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1200\/JCO.2007.11.3357","article-title":"Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study","volume":"25","author":"Fuchs","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdw206","article-title":"Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)","volume":"27","author":"Yamazaki","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2004.01.140","article-title":"Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive Group Study-FFCD 9803","volume":"22","author":"Bondoux","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/sj.bjc.6602649","article-title":"Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer","volume":"92","author":"Moehler","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/annonc\/mdn166","article-title":"Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction","volume":"19","author":"Dank","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/jjco\/hyn109","article-title":"Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution","volume":"38","author":"Nakashima","year":"2008","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/CAD.0b013e328345b509","article-title":"Randomized phase II trial of first-line treatment with tailored irinotecan plus S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301)","volume":"22","author":"Komatsu","year":"2011","journal-title":"Anti-Cancer Drugs"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMoa003034","article-title":"Irinotecan plus cisplastin compared with etoposide plus cisplastin for extensive small-cell lung cancer","volume":"346","author":"Noda","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0169-5002(03)00075-8","article-title":"Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer","volume":"40","author":"Hirose","year":"2003","journal-title":"Lung Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3816\/CLC.2005.n.029","article-title":"Phase II trial of gemcitabine\/irinotecan in refractory or relapsed small-cell lung cancer","volume":"7","author":"Schuette","year":"2005","journal-title":"Clin. Lung Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1200\/JCO.2006.06.5821","article-title":"Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer","volume":"24","author":"Szczesna","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1183\/09031936.06.00015605","article-title":"Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer","volume":"27","author":"Huber","year":"2006","journal-title":"Eur. Respir. J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.bjc.6603079","article-title":"Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer","volume":"94","author":"Kinoshita","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1200\/JCO.2006.08.3998","article-title":"Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer","volume":"25","author":"Eckardt","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00280-007-0496-6","article-title":"Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer","volume":"61","author":"Ohyanagi","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1200\/JCO.2008.18.1974","article-title":"Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan lung cancer study group trial 0402","volume":"26","author":"Inoue","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00280-008-0690-1","article-title":"Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer","volume":"62","author":"Park","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1200\/JCO.2008.20.2127","article-title":"Phase II Trial of Irinotecan and Carboplatin for Extensive or Relapsed Small-Cell Lung Cancer","volume":"27","author":"Chen","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.2008.20.1061","article-title":"Phase III trial of irinotecan\/cisplatin compared with etoposide\/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124","volume":"27","author":"Lara","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/annonc\/mdq036","article-title":"A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease","volume":"21","author":"Zatloukal","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1200\/JCO.2010.29.8851","article-title":"Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy","volume":"29","author":"Jotte","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1093\/annonc\/mdq652","article-title":"Arbeitsgemeinschaft Internistische Onkologie Thoracic Oncology Study Group. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer","volume":"22","author":"Schmittel","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00280-010-1427-5","article-title":"A multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer","volume":"68","author":"Xenidis","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2013.54.5392","article-title":"Randomized phase III trial of Amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer","volume":"32","author":"Gervais","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/1759-7714.12303","article-title":"Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial","volume":"6","author":"Shi","year":"2015","journal-title":"Thorac. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/JTO.0000000000000588","article-title":"Cabazitaxel versus topotecan in patients with small-cell lung cancer with progressive disease during or after first-line platinum-based chemotherapy","volume":"10","author":"Evans","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(16)30104-8","article-title":"Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): A multicentre, open-label, randomised phase 3 trial","volume":"17","author":"Goto","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1634\/theoncologist.2016-0220","article-title":"A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients with Relapsed Small-Cell Lung Cancer","volume":"21","author":"Chiappori","year":"2016","journal-title":"Oncologist"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00280-016-2983-0","article-title":"Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer","volume":"77","author":"Trafalis","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000486622","article-title":"A Phase II Study of Irinotecan for Patients with Previously Treated Small-Cell Lung Cancer","volume":"94","author":"Kondo","year":"2018","journal-title":"Oncology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4143\/crt.2018.019","article-title":"Randomized phase III trial of irinotecan plus cisplatin versus etoposide plus cisplatin in chemotherapy-na\u00efve Korean patients with extensive-disease small cell lung cancer","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(20)30461-7","article-title":"Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: An open-label, multicentre, randomised, phase 3 trial","volume":"21","author":"Baize","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41416-020-01055-5","article-title":"A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer","volume":"124","author":"Kang","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jtho.2022.07.062","article-title":"OA12.05 Phase 1 Updated Exploration and First Expansion Data for DLL3-targeted T-cell Engager Tarlatamab in Small Cell Lung Cancer","volume":"17","author":"Borghaei","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.lungcan.2022.03.003","article-title":"Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer","volume":"166","author":"Edelman","year":"2022","journal-title":"Lung Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2007.15.7545","article-title":"Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: A randomized phase III trial","volume":"26","author":"Hermes","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1634\/theoncologist.12-1-38","article-title":"The continuum of care: A paradigm for the management of metastatic colorectal cancer","volume":"12","author":"Goldberg","year":"2007","journal-title":"Oncologist"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1093\/annonc\/mds236","article-title":"ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making","volume":"23","author":"Schmoll","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.soc.2017.05.007","article-title":"An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma","volume":"26","author":"Ikoma","year":"2017","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3760\/cma.j.issn.0366-6999.20131490","article-title":"Chemotherapy with or without irinotecan in patients with advanced or recurrent gastric cancer: A meta-analysis of randomized controlled trials","volume":"127","author":"Zeng","year":"2014","journal-title":"Chin. Med. J. (Engl.)"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"VIII228","DOI":"10.1093\/annonc\/mdy282.063","article-title":"Meta-analysis of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer","volume":"29","author":"Nishikawa","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4143\/crt.2015.452","article-title":"Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis","volume":"49","author":"Cho","year":"2016","journal-title":"Cancer Res. Treat."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mco.2021.2383","article-title":"Topotecan or other agents as second-line therapy for relapsed small-cell lung cancer: A meta-analysis of randomized studies","volume":"15","author":"Petrelli","year":"2021","journal-title":"Mol. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2005.04.8595","article-title":"Randomized phase III trial comparing irinotecan\/cisplatin with etoposide\/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer","volume":"24","author":"Hanna","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/22\/3802\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:30:38Z","timestamp":1760113838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/22\/3802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":92,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["cancers16223802"],"URL":"https:\/\/doi.org\/10.3390\/cancers16223802","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,12]]}}}